Lexicon Pharma

Q2 FY2026 EarningsQ2 FY26 results significantly missed consensus expectations on both top and bottom lines. Revenue of $0.69M fell 82.7% short of the $4.00M estimate, primarily due to lower-than-expected INPEFA sales. GAAP EPS was -$0.07 vs. the -$0.05 mean estimate, weighed down by a $4.3M loss on debt extinguishment and rising R&D costs related to the Phase 3 SONATA-HCM trial. While clinical milestones remain on track, the widening loss and revenue miss underscore commercialization challenges.